Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhII suggests biomarker-indication for Roche advanced AMD drug

This article was originally published in Scrip

Executive Summary

Roche's lampalizumab has met its Phase II primary endpoint in the MAHALO study, slowing the progression of geographic atrophy – an advanced form of dry age-related macular degeneration (dry AMD). The bad news: significant efficacy was only seen in patients dosed monthly (so patients won’t be able to dose once every other month to reduce the number of times they have to have needles stuck in their eyes). But the good news for Roche is that the drug seemed to perform twice as well in a biomarker-defined subset of patients.

You may also be interested in...



Roche's Dry AMD Drug Lampalizumab Delivers Disappointment In Phase III

Analysts had already been doubtful about the prospects for success in the Spectri study. A second Phase III trial is ongoing, but the candidate is already being removed from revenue models.

WuXi eases CAR-T manufacturing burden with new US plant

China's WuXi PharmaTech, an R&D technology company serving the pharmaceutical, biotechnology and medical device industries, has announced construction of a new manufacturing facility in Philadelphia, US designed for cell therapy products, including chimeric antigen receptor T-cell (CAR-T) therapies. More manufacturing power is crucial to the success of this burgeoning, high-potential field.

NICE lifts Entyvio restrictions after Takeda offers discount

Takeda has managed to persuade NICE, the health technology appraisal institute for England and Wales, to recommend its ulcerative colitis drug Entyvio (vedolizumab) without the restrictions the institute had previously stipulated – as long as the company offers a discount via a patient access scheme.

UsernamePublicRestriction

Register

RS009715

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel